SOURCE: Xtalks

Xtalks Webinars

January 11, 2016 15:00 ET

Top News Stories You Might Have Missed From Xtalks

TORONTO, ON--(Marketwired - January 11, 2016) - Check out all news stories here:
Subscribe to our weekly newsletter:

Xtalks provides current articles daily in the life science industry.

90 Percent Of Americans Consume An Excess Of Salt According To The CDC -
(Jan 11) According to a report conducted by the Centers for Disease Control and Prevention (CDC), nine in every ten Americans ingest more than what is recommended for daily sodium intake.

Elsevier Launches New Open Access Journal For Clinical Trial Professionals -
(Jan 11) Elsevier Launches New Open Access Journal For Clinical Trial Professionals.

Charles River Announces Acquisition of WIL Research -
(Jan 8) Contract research organization (CRO) Charles River Laboratories announced they had entered into an agreement to acquire WIL Research for an estimated $585 million

Roche Looks To Assess Arthritis Drug As Possible Treatment For PAH -
(Jan 8) Swiss drugmaker Roche has formed an alliance with the UK's Department of Health to conduct a series of clinical trials aimed at determining whether the company's arthritis biologic, tocilizumab (or Actemra), is effective at treating pulmonary arterial hypertension (PAH)

Sanofi To Cease Marketing Of MannKind's Inhaled Insulin, Afrezza -
(Jan 7) The company says the decision was made based on the lackluster number of prescriptions for Afrezza, despite launching a targeted "Surprise, it's insulin" campaign in 2015, along with additional investments in marketing.

American Association Of Advertising Agencies To Lobby Against Proposed DTC Ad Ban -
(Jan 7) The advertising trade group known as the American Association of Advertising Agencies (4A's) published an op-ed piece on on Monday promising to defend the industry's right to use direct-to-consumer (DTC) ads for pharmaceuticals and medical devices.

Diagnostic Test Developer bioMérieux Receives FDA Class I Recall -
(Jan 6) Just before the end of 2015, France-based antibiotic test developer, bioMérieux, received notice that their diagnostic tests would be subject to a US Food and Drug Administration (FDA) Class I recall due to the risks that the tests could produce false positives.

Indian Pharmaceutical Manufacturer, Cadila, Receives FDA Warning Letter -
(Jan 6) Cadila Healthcare is the latest to receive a warning letter from the agency for activities conducted at the company's plants in Moraiya and Ahmedabad, though as of yet it's unknown exactly what issues were identified at the facilities.

KaloBios Files For Bankruptcy Following Martin Shkreli's December Arrest -
(Jan 5) Now that Shkreli is facing up to 20 years in prison for allegedly committing securities fraud, KaloBios' revival was short-lived as they file for Chapter 11.

Bayer and CRISPR Therapeutics Collaborate To Develop Cures For Genetic Diseases -
(Jan 5) Late last month, Bayer and CRISPR Therapeutics announced their intention to form a joint venture combining the CRISPR-Cas9 gene editing tool created by its namesake company with Bayer's knowledge of disease treatment.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit
For information about hosting a webinar visit

Contact Information